Celixir 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heartcel (iMP cell therapy) / Celixir
2017-000516-42: A Phase IIB Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery.

Not yet recruiting
2
50
Europe
Allogeneic Human Immunomodulatory Progenitor (iMP) cells (Heartcel), Injection
Cell Therapy Ltd (trading as Celixir), Cell Therapy Ltd (trading as Celixir)
Ischaemic heart disease post MI, Treatment of ischaemic heart disease post heart attack, Diseases [C] - Cardiovascular Diseases [C14]
 
 

Download Options